⚠️ Neutral
Listed
Pharmaceuticals & Biotechnology
Symbiotec Pharmalab Limited IPO
₹1,757 Cr · Fresh Issue & OFS · Pharmaceuticals & Biotechnology
Price Band
₹938 – ₹988
GMP (Grey Market)
—
No GMP data yet
Issue Size
₹1,757 Cr
Fresh Issue & OFS
Market Cap
₹6,244.43 Cr
At upper band
P/E Ratio
56.8x
P/S: 7.2x
Listing Date
01 Sep 2026
BSE & NSE
IPO Timeline
✓
Opens
24 Aug 2026
✓
Closes
27 Aug 2026
✓
Allotment
28 Aug 2026
✓
Refund
31 Aug 2026
✓
Listing
01 Sep 2026
IPO India Hub: Neutral
Conviction
5/10
The company trades at 1.42× sector midpoint with a 56.8x P/E, within Subscribe range, but weak profit growth (4.8% PAT CAGR) and a 91.4% OFS raise—primarily debt repayment rather than growth capex—create execution uncertainty. Monitor debt reduction impact on future returns.
Listing Performance
Issue Price
₹988
Allotment price
Listing Price
₹978.2
-0.99% on listing day
Current Price (CMP)
₹1133.45
+14.7% vs issue
Listed On
01 Sep 2026
BSE & NSE
Our Analysis — Key Points
✓ Strength
Strong EBITDA margin and cash generation
The company maintains a 27.26% EBITDA margin, indicating efficient operations and pricing power in the pharmaceutical sector. This margin level supports the current valuation and provides a buffer during market downturns.
✓ Strength
Reputed lead manager syndicate
JM Financial, Avendus Capital, Motilal Oswal, and Nomura bring institutional credibility and distribution strength. The 75.08× subscription overrun signals strong retail and institutional demand despite valuation concerns.
⚠ Risk
Weak profit growth trajectory
PAT CAGR of only 4.8% over two years, with net profit declining from ₹100.1 Cr (FY-2) to ₹96.8 Cr (FY-1) before recovering to ₹109.9 Cr (FY0), signals operational headwinds or margin compression. Revenue growth of 9.8% CAGR does not translate to earnings expansion.
⚠ Risk
Massive OFS dilutes growth narrative
91.4% of the ₹1,757 Cr issue is OFS (secondary sale by promoters), not primary capital for expansion. ₹112.5 Cr of net proceeds goes to debt repayment, leaving only ₹29.5 Cr for corporate purposes—insufficient for meaningful capex or R&D acceleration.
₹ Valuation
P/E at sector midpoint but margin below threshold
At 56.8x P/E (1.42× the 40× healthcare midpoint) with NPM of 12.6%, the company falls short of the 15% margin threshold that would justify Subscribe conviction. The 7.2x P/S ratio is reasonable but does not offset earnings growth weakness.
👁 Watch
Post-listing debt reduction and ROCE recovery
ROCE of 11.8% is below cost of capital for most investors. Track whether debt repayment materially improves ROCE and whether management deploys remaining cash into high-return R&D or capacity expansion rather than further shareholder returns.
Top Analyst Reviews
| Analyst / Firm | Rating | Known For | Review |
|---|---|---|---|
| IPO India Hub Our independent review |
Original analysis based on DRHP & public financials | This page | |
| Dilip Davda Chittorgarh.com |
India's most followed independent IPO analyst | Search on Chittorgarh → | |
| Capital Market (CM Rating) CapitalMarket.com |
Widely-cited "New Issue Monitor" reports | Search on CapitalMarket → | |
| ICICI Securities ICICIdirect Research |
SEBI-registered broker research desk | Visit ICICIdirect → | |
| IPO Guru Analyst Leaderboard ipoguru.in |
Ranks 49 analysts by real IPO outcome accuracy | View leaderboard → |
External links go to each platform's IPO section — search for "Symbiotec Pharmalab Limited" to find the specific review. IPO India Hub does not represent the accuracy of third-party ratings.
Company Snapshot
Revenue
₹869.15 Cr
Net Profit
₹109.90 Cr
Industry
Pharmaceuticals & Biotechnology
Issue Type
Fresh Issue & OFS
Promoters
ANIL SATWANI, KASHISH SATWANI, SUSHIL SATWANI AND SATWANI HOLDINGS LLP
Lead Managers
JM Financial, Avendus Capital, Motilal Oswal Investment Advisors and Nomura Financial Advisory
Quick Actions
Frequently Asked Questions
Neutral. The company trades at 1.42× sector midpoint with a 56.8x P/E, within Subscribe range, but weak profit growth (4.8% PAT CAGR) and a 91.4% OFS raise—primarily debt repayment rather than growth capex—create execution uncertainty. Monitor debt reduction impact on future returns.
GMP data is not yet available for this IPO. Check our GMP Live page for the latest updates closer to the listing date.
Lot size details will be updated when the DRHP is filed. The price band is ₹938 – ₹988.
The IPO opens on 24 Aug 2026. It closes on 27 Aug 2026. Allotment is expected on 28 Aug 2026. Refunds initiate on 31 Aug 2026. Listing on BSE and NSE is on 01 Sep 2026.
The lead managers for the IPO are JM Financial, Avendus Capital, Motilal Oswal Investment Advisors and Nomura Financial Advisory. Check the SEBI filing for the registrar details.
The IPO listed on 01 Sep 2026 at ₹978.2 against an issue price of ₹988 (-0.99% on listing day). The current market price (CMP) is approximately ₹1133.45 (14.7% vs issue).
Our analysis is <strong>Neutral</strong>. Consider applying selectively before the issue closes on 27 Aug 2026. The company trades at 1.42× sector midpoint with a 56.8x P/E, within Subscribe range, but weak profit growth (4.8% PAT CAGR) and a 91.4% OFS raise—primarily debt repayment rather than growth capex—create execution uncertainty. Monitor debt reduction impact on future returns.
Our analysis is <strong>Neutral</strong>. Consider applying selectively before the issue closes on 27 Aug 2026. The IPO is priced at a P/E of 56.8x. Market cap at issue price is ₹6,244.43 Cr. As with all IPOs, please read the DRHP and assess your own risk tolerance before investing.
You can apply via UPI through your broker's trading app (Zerodha, Upstox, Fyers, etc.) or via ASBA through your net banking portal. The issue closes on 27 Aug 2026, so apply before that date. Step 1: Log in to your broker or bank app. Step 2: Go to IPO section and search for 'Symbiotec Pharmalab Limited'. Step 3: Enter the number of lots and UPI ID. Step 4: Accept the mandate on your UPI app.
Explore More